MORGAN STANLEY PLC/CALL/MEDTRONIC/90/0.1/20.12.24 Share Price

Warrant

DE000MB8M3T9

Market Closed - Börse Stuttgart 19:22:32 28/06/2024 BST
0.126 EUR +5.88% Intraday chart for MORGAN STANLEY PLC/CALL/MEDTRONIC/90/0.1/20.12.24
Current month-34.72%
1 month-44.25%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
28/06/24 0.126 +5.88%
27/06/24 0.119 -9.85%
26/06/24 0.132 -6.38%
25/06/24 0.141 -16.07%
24/06/24 0.168 -2.33%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 07:22 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer Morgan Stanley
WKN MB8M3T
ISINDE000MB8M3T9
Date issued 12/07/2023
Strike 90 $
Maturity 20/12/2024 (175 Days)
Parity 10 : 1
Emission price 0.96
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 1.05
Lowest since issue 0.119
Delta0.22x
Omega 12.48
Premium16.09x
Gearing57.19x
Moneyness 0.8746
Difference Strike 11.29 $
Difference Strike %+12.54%
Spread 0.003
Spread %2.31%
Theoretical value 0.1285
Implied Volatility 21.61 %
Total Loss Probability 82.00 %
Intrinsic value 0.000000
Present value 0.1285
Break even 91.38 €
Theta-0.01x
Vega0.01x
Rho0.01x

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
78.71 USD
Average target price
94.02 USD
Spread / Average Target
+19.46%
Consensus